1. Inicio
  2. Publicaciones
  3. Effectiveness and safety of different azacitidine dosage regimens in patients with myelodysplastic syndromes or acute myeloid leukemia

Effectiveness and safety of different azacitidine dosage regimens in patients with myelodysplastic syndromes or acute myeloid leukemia

Fecha de publicación:

Autores de IIS La Fe

Participantes ajenos a IIS La Fe

  • García-Delgado R
  • de Miguel D
  • Bailén A
  • González JR
  • Bargay J
  • Falantes JF
  • Tormo M
  • Brunet S
  • Figueredo A
  • Casaño J
  • Medina A
  • Badiella L
  • Jurado AF

Grupos

Abstract

We investigated the effectiveness and tolerability of azacitidine in patients with World Health Organization-defined myelodysplastic syndromes, or acute myeloid leukemia with 20-30% bone marrow blasts. Patients were treated with azacitidine, with one of three dosage regimens: for 5 days (AZA 5); 7 days including a 2-day break (AZA 5-2-2); or 7 days (AZA 7); all 28-day cycles. Overall response rates were 39.4%, 67.9%, and 51.3%, respectively, and median overall survival (OS) durations were 13.2, 19.1, and 14.9 months. Neutropenia was the most common grade 3-4 adverse event. These results suggest better effectiveness-tolerability profiles for 7-day schedules. (C) 2014 The Authors. Published by Elsevier Ltd.

Datos de la publicación

ISSN/ISSNe:
0145-2126, 1873-5835

LEUKEMIA RESEARCH  PERGAMON-ELSEVIER SCIENCE LTD

Tipo:
Article
Páginas:
744-750
PubMed:
24795069
Factor de Impacto:
1,047 SCImago ℠
Cuartil:
Q2 SCImago ℠

Citas Recibidas en Web of Science: 41

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • Acute myeloid leukemia; Azacitidine; Dosing schedules; Myelodysplastic syndromes; Overall survival; Safety

Campos de Estudio

Cita

Compartir